Surrozen Inks First Partnership With BI For Wnt-Targeted Retinopathy Candidate

 
• By Joseph Haas

German pharma takes global rights to preclinical bispecific antibody, while Surrozen will focus on Phase I candidates for inflammatory bowel disease and alcoholic hepatitis.

Surrozen deal
Surrozen inks first partnership based on new approach to targeting Wnt • Source: Shutterstock

More from Deals

More from Business